• OUTLOOK ARENA
  • VIEWS ON NEWS
  • AUGUST 4, 2003

Cipla: Margins under pressure

Domestic pharma major, Cipla announced its first quarter FY04 results recently. While the company has posted a 13% increase in the topline, a marginal drop in the operating efficiency has restricted the company's bottomline growth at 11%. Let us briefly evaluate the performance of the company during 1QFY04.

(Rs m)1QFY031QFY04Change
Net Sales4,0304,54212.7%
Other Income486739.7%
Total expenditure3,2073,66914.4%
Operating Profit (EBDIT)8238746.2%
Operating Profit Margin (%)20.4%19.2% 
Interest210330.4%
Depreciation708825.0%
Profit before Tax7988435.6%
Tax192171-10.9%
Profit after Tax/(Loss)60667210.8%
Net profit margin (%)15.0%14.8% 
No. of Shares (m)60.060.0 
Earnings per share*40.444.8 
Current P/e ratio 18.0 
*(annualised)   

Cipla recorded a healthy growth in the net sales. However, a 25% rise in the raw material expense has affected the margins of the company. Raw material cost as a percentage of sales has gone up from 44% in 1QFY03 to 49% in the current quarter. This was primarily due to the change in the product mix of the company. Depreciation charges were also on the higher side on account of provision being made for the second phase of the Goa unit, which commenced commercial production during the quarter under review. Other income increased due to higher export benefits received during the current quarter. A drop in operating profit margins, sharp rise in the interest cost and a drop in the tax provisions on account of Sec 80I benefits have resulted in Cipla registering an 11% rise in net profits. Let us now study the revenue break up of the company.

Revenue break-up
(Rs m)1QFY031QFY04Change
Domestic 2,624 3,054 16.4%
Exports:   
Formulations 507 884 74.3%
Bulk drugs 882 562 -36.3%
Other operating income 16 42 161.1%
Total 4,030 4,542 12.7%

A close examination of the revenues indicates that although the export of formulations saw a steep rise, bulk drugs exports registered a sharp decline. This was on account of postponement of purchases by customers due to delay in patent rulings. On the domestic front, Cipla managed to outperform the industry with strong performance in the anti-biotic, anti-asthmatics and anti-hypertensives segments. The company has launched ‘Tiotropium’, a dry powder inhaler in the anti-asthma segment during the current quarter. Exports of formulations have seen a 74% growth. The growth was fuelled by good performance in the anti-AIDS segment.

Cipla has indicated that the export of CFC - free inhalers to Europe will commence as soon as the required regulatory approvals are received. However, the company has refused to give a time frame within which it expects to receive the requisite approval.

At Rs 807, Cipla is trading at a P/E of 18x its 1QFY04 earnings. Given the company’s ability to outperform in the domestic markets and the likely approval for export of CFC - free inhalers, the prospects of the company seem bright. However, delay in regulatory approval for products for which Cipla is the bulk drugs supplier and the uncertainty in respect of DPCO remain a cause for concern.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407